CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance

Therapeutic Drug Monitoring

Volumn 33, Issue 3, 2011, Pages 369-371

  Pashaee, Nilufar ^a   Bouamar, Rachida ^a   Hesselink, Dennis A ^a   Roodnat, Joke I ^a   Van Schaik, Ron H N ^a   Weimar, Willem ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CYP3A5; Intrapatient variability; Kidney transplantation; Pharmacogenetics; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; DRUG CLEARANCE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; INDIVIDUALITY; INTRAPATIENT VARIABILITY; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 80051770645     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31821a7aa3     Document Type: Article

References (16)

1. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757-2763.
2. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
3. Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics. 2007;8:835-849. (Pubitemid 47288980)
4. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87: 721-726.
5. van Gelder T, Hesselink DA. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome? Clin Pharmacol Ther. 2010; 87:640-641.
6. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391. (Pubitemid 32268418)
7. Yong Chung J, Jung Lee Y, Bok Jang S, et al. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit. 2010;32:67-72.
8. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African- American men and women. Pharmacogenetics. 2003;13:595-606. (Pubitemid 37311146)
9. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254. (Pubitemid 37083100)
10. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48: 1668-1671.
11. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimustreated renal transplant recipients. Pharmacogenet Genomics. 2008;18: 339-348. (Pubitemid 351367527)
12. Ng FL, Holt DW, Chang RW, et al. Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. Nephrol Dial Transplant. 2010;25:628-634.
13. Kuypers DR, de Jonge H, Naesens M, et al. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics. 2008;18:861-868.
14. Chandel N, Aggarwal PK, Minz M, et al. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genomics. 2009;19:458-463.
15. van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25: 707-712. (Pubitemid 34983373)
16. Tielen M, van Staa AL, Jedeloo S, et al. Q-methodology to identify young adult renal transplant recipients at risk for nonadherence. Transplantation. 2008;85:700-706. (Pubitemid 351398246)